



EHDN Clinical Research Congress 2026 22nd – 24th October 2026, Kraków, Poland

**Preliminary programme – status August 11*

THURSDAY, 22nd OCTOBER, 2026

07:30 – 08:30 REGISTRATION DESK

08:30 – 09:00 WELCOME AND INTRODUCTION

Chaired by Patrick Weydt, Cristina Sampaio and Danuta Lis

09:00 – 09:45 PLENARY SESSION I: HD Burden - Family and Patient Perspective

Chaired by Åsa Petersén

Speakers: Charlotte Spearing, Greg Witkowski and William Gray

09:45 – 10:30 PLENARY SESSION II: Navigating the Therapeutic Pipeline in Huntington's Disease

Chaired by Swati Sathe and Pavlina Stefanova-Konstantinova

1. The Race to treat Huntington's disease: where have we come over the past decade

Anne Rosser

2. Future Challenges and Opportunities in the Clinical Development of Huntington's Disease Therapies

Cristina Sampaio

10:30 – 11:00 **BREAK**

11:00 – 12:00 PARALLEL SESSIONS I

A. Psychological interventions in Huntington's Disease: a transdiagnostic perspective

Chaired by Docia Demmin and Lucienne van der Meer

1. Keeping Yourself in Mind:

Acceptance and Commitment

Therapy programmes for people affected by Huntington's Disease

Sarah Gunn

2. Resilient together-ALS: an early dyadic intervention for patients and their informal care-partners

Christina Rush

3. Reducing anxiety in people with HD using a guided self-help intervention

Jane Simpson and Maria Dale

B. Learning Across Neurodegenerative Diseases: Clinical Trial Innovation, Design, and Ethics

Chaired by Patrick Weydt and Ruben van Eijk

1. Lessons and innovations in clinical trials for Amyotrophic Lateral Sclerosis

Ruben van Eijk

2. Looking back - looking forward: insights into clinical trial design and determination of clinical meaningfulness

Michael Hayden

3. Placebo-controlled surgical trials: an ethical overview

Cindy Towns

12:00 – 13:30 **LUNCH and POSTER VIEWING**



13:30 – 14:30

PARALLEL SESSIONS II

A. Digital Biomarkers and Artificial Intelligence

Chaired by Jean-Marc Burgunder and Matt Roche

1. **Sensitivity, Validity, and Utilization of the HDDMS in Clinical Trials**
Jonas Dorn
2. **Q-Motor results from AMT-130**
David Margolin
3. **Applications and Opportunities of Digital Twins in Clinical Trials**
Ann-Kathrin Schalkamp
4. **Panel Discussion and Q&A**

B. Social Cognition

Chaired by Sarah Mason and Rebecca Fuller

1. **Reading minds missing people: Ecological validity problem in social cognition**
Erin Heerey
2. **Cling Film, Text Messages and Work - Three ethnographic stories of early social cognitive change in Huntington's disease**
Alex Fisher
3. **Talk III**
TBA
4. **Panel Discussion**

14:30 – 14:35

Transition BREAK

14:35 – 15:15

EHDN BUSINESS MEETING

Chaired by Patrick Weydt and Åsa Petersén

15:15 – 15:45

BREAK

15:45 – 16:45

KEYNOTE LECTURE I: Genetic Testing and Genetic Modifiers

Chaired by Nayana Lahiri and Hoa Huu Phuc Nguyen

Speaker: Alexandra Durr

16:45 – 17:45

DEBATE: Implementation of Genetic Modifier Data into Clinical Practice – Are we there, yet?

Chaired by Nayana Lahiri and Hoa Huu Phuc Nguyen

Speaker: Michael Hayden, Alexandra Durr, Robert Klitzman, Ashleigh Mclellan and Darren Monckton

17:45 – 22:00

NETWORKING EVENING

Posters, Art Exhibition, Finger Food & Drinks



FRIDAY, 23rd OCTOBER, 2026

08:00 – 08:45 **PLENARY SESSION III: Access and Affordability for the HD Community**

Chaired by Hugh Rickards and Jenna Heilman

3. **HEATED (Huntington's Equal Access to Effective Drugs). The story so far.**
Hugh Rickards
4. **What are the barriers to access to effective drugs in HD and how do we overcome them?**
Josie Godrey
5. **Access to effective HD drugs: the global perspective**
Nacho Sanjuan

08:45 – 09:45 **UPDATE ON ONGOING CLINICAL TRIALS**

Chaired by Jenny Townhill and Ralf Reilmann

1. **Alnylam**
Sarah Tabrizi
2. **VICO Therapeutics**
Scott Schobel
3. **Skyhawk Therapeutics**
Meghan Miller
4. **Placebo Response in Recent HD Randomized Clinical Trials**
Jeffrey Long
5. **Panel Discussion and Q&A**

09:45 – 10:00 **BREAK**

10:00 – 11:00 **PARALLEL SESSIONS III**

A. Modifiers of Huntington's Disease: Genetic, Biological, and Preclinical Perspectives

Chaired by Marta Biagioli and Vahri Beaumont

1. **PMS1/MLH1 variants and drugging the PMS1 ATPase site**
Tom Massey
2. **MED15 as a Non-MMR Modifier of Huntington's Disease**
Mahmoud Pouladi
3. **hiPSC cell models**
Mike Flowers

B. Glymphatic Imaging

Chaired by Daniel Claassen and Andrew Wood

1. **Why the Glymphatic System Deserves Our Attention**
Daniel Claassen
2. **Imaging Human Glymphatic Function with Intrathecal Contrast: From Method to Clinical Readout**
Kristian Eide
3. **Imaging the Glymphatic System in Huntington's Disease and Neurodegeneration: Implications for Monitoring and Neurotherapeutics**
Manus Donahue

11:00 – 11:30 **BREAK**

11:30 – 12:30 **KEYNOTE LECTURE II: The ubiquitin proteolytic system - from a hypothetical assumption of why it should exist to human diseases and drug development**

Chaired by Hoa Huu Phuc Nguyen

Speaker: Prof. Dr. Aaron Ciechanover (Nobel Prize Winner for Chemistry 2004)



- 12:30 – 14:30 **LUNCH, POSTER VIEWING and SPECIAL SESSIONS**
- | | | |
|---|--|--|
| <p>a. HDYO and EHA
13:15–14:15
Chaired by Jenna Heilman and Astri Arnesen</p> | <p>b. EHDN Fellowship
13:15–14:15
Chaired by Juliana Bronzova and Fionnuala Margreiter</p> | <p>c. Local Language Session
13:00–15:30
Chaired by Danuta Lis and Daniel Zielonka</p> |
|---|--|--|
- 14:30 – 15:30 **SHORT COMMUNICATIONS I**
Presentation of selected abstracts
Chaired by Davina Hensman Moss and Jiří Klempíř
- 15:30 – 16:30 **PLENARY SESSION IV: Advanced Biomarkers**
Chaired by Hilary Wilkinson and Niels Skotte
1. **Lipidomics and new biomarkers**
William Griffiths
 2. **PENK & NEFL**
Niels Skotte and Hilary Wilkinson
 3. **HD YAS 3.0**
Rachael Scahill
- 16:30 – 17:00 **BREAK**
- 17:00 – 18:00 **PANEL DISCUSSION: Clinical Trial Communications in Context - Rules, Responsibilities, and Community Expectations**
Chaired by Emily Gantman and Ed Wild
Panel: Charlotte Spearing, Mai-Lise Nguyen, Rachel Harding and David Anderson

SATURDAY, 24th OCTOBER, 2026

- 08:30 – 09:15 **EHDN LIGHTNING PRESENTATIONS**
Chaired by Duncan McLauchlan and Agnieszka Fiszer
1. **Lightning Presentation on awarded EHDN Strategic Funds**
Nayana Lahiri, Camilla Ekwall and Cheney Drew
 2. **The expanded HTT CAG repeat is a DNA repair hotspot where unscheduled DNA synthesis serves as a sensitive biomarker of somatic instability**
Verónica Inés Brito
 3. **LTS-201: An AAV Gene Therapy Targeting MSH3 for Huntington's Disease**
Jang-Ho Cha
 4. **LQT-23: a small molecule MSH3 inhibitor targeting somatic instability in Huntington's disease**
Caroline L. Benn
- 09:15 – 10:15 **PLENARY SESSION V: Efficacy Demonstration - Standards, Measures and Endpoints**
Chaired by Ahmad Aziz and Jamie Hamilton
1. **Analysis of Enroll-HD TMS training data**
Matt Roche
 2. **Analytical Considerations for Contextualizing Outcomes and Estimating Treatment Effects in Huntington's Disease Clinical Trials with Partial or no Internal Control Using External Cohort Data**
Angelika Caputo
 3. **MCID within the context of other Neurodegenerative disorders**
Glenn Stebbins



10:15 – 10:45 **BREAK**

10:45 – 11:45 **SHORT COMMUNICATIONS II**
Presentation of selected abstracts
Chaired by Mayke Oosterloo and Arun Karpur

11:45 – 12:45 **From Clinical Trial Progress and Regulatory Perspectives**
Chaired by Bernhard Landwehrmeyer and Daniel Weintraub

- 1. Regulatory perspectives on trial innovation and clinical meaningful outcomes**
Elena Hernández Martínez de Lapiscina
- 2. Tominersen: GENERATION HD2 Results and Key Learnings**
Peter McColgan
- 3. Votoplam: Phase 2 Results and Phase 3 INVEST-HD study update**
Beth Borowsky
- 4. Panel Discussion and Q&A**
Elena Hernández Martínez de Lapiscina, Peter McColgan, Beth Borowsky, Anne Rosser and Dina De Sousa

12:45 – 13:10 **SUMMARY AND POSTER AWARD**
Chaired by Nayana Lahiri and Hoa Huu Phuc Nguyen

13:10 – 13:15 **FAREWELL**
Chaired by Patrick Weydt and Cristina Sampaio